Macrogenics Inc (NASDAQ: MGNX)’s stock price has gone rise by 5.44 in comparison to its previous close of 3.40, however, the company has experienced a -0.42% decrease in its stock price over the last five trading days. globenewswire.com reported 2024-10-30 that ROCKVILLE, MD, Oct. 30, 2024 (GLOBE NEWSWIRE) — MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today announced that Scott Koenig, M.D., Ph.D., intends to step down as President and Chief Executive Officer early next year. The Company’s Board of Directors has retained Heidrick & Struggles to lead a search process to identify its next Chief Executive Officer and has established a special committee of the Board to oversee the transition process.
Is It Worth Investing in Macrogenics Inc (NASDAQ: MGNX) Right Now?
The stock has a 36-month beta value of 2.09. Opinions on the stock are mixed, with 4 analysts rating it as a “buy,” 5 as “overweight,” 2 as “hold,” and 0 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for MGNX is 58.01M, and at present, short sellers hold a 9.25% of that float. On October 31, 2024, the average trading volume of MGNX was 747.97K shares.
MGNX’s Market Performance
MGNX’s stock has seen a -0.42% decrease for the week, with a 1.56% rise in the past month and a -6.40% fall in the past quarter. The volatility ratio for the week is 7.73%, and the volatility levels for the past 30 days are at 6.42% for Macrogenics Inc The simple moving average for the past 20 days is -4.88% for MGNX’s stock, with a -59.19% simple moving average for the past 200 days.
Analysts’ Opinion of MGNX
B. Riley Securities gave a rating of “Neutral” to MGNX, setting the target price at $5 in the report published on July 31st of the current year.
MGNX Trading at 1.45% from the 50-Day Moving Average
After a stumble in the market that brought MGNX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -83.62% of loss for the given period.
Volatility was left at 6.42%, however, over the last 30 days, the volatility rate increased by 7.73%, as shares surge +1.41% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading unchanged at present.
During the last 5 trading sessions, MGNX remain unchanged, which changed the moving average for the period of 200-days by -65.88% in comparison to the 20-day moving average, which settled at $3.77. In addition, Macrogenics Inc saw -62.73% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at MGNX starting from Peters Jeffrey Stuart, who sale 51,395 shares at the price of $15.55 back on Apr 04 ’24. After this action, Peters Jeffrey Stuart now owns 0 shares of Macrogenics Inc, valued at $799,148 using the latest closing price.
Peters Jeffrey Stuart, the Senior VP and General Counsel of Macrogenics Inc, sale 19,625 shares at $21.50 during a trade that took place back on Mar 06 ’24, which means that Peters Jeffrey Stuart is holding 8,895 shares at $421,938 based on the most recent closing price.
Stock Fundamentals for MGNX
Current profitability levels for the company are sitting at:
- -4.8 for the present operating margin
- 0.74 for the gross margin
The net margin for Macrogenics Inc stands at -3.32. The total capital return value is set at -1.37. Equity return is now at value -118.91, with -53.82 for asset returns.
Based on Macrogenics Inc (MGNX), the company’s capital structure generated 0.37 points at debt to capital in total, while cash flow to debt ratio is standing at -4.5. The debt to equity ratio resting at 0.59. The interest coverage ratio of the stock is 114.34.
Currently, EBITDA for the company is -158.6 million with net debt to EBITDA at 0.26. When we switch over and look at the enterprise to sales, we see a ratio of 4.33. The receivables turnover for the company is 6.63for trailing twelve months and the total asset turnover is 0.2. The liquidity ratio also appears to be rather interesting for investors as it stands at 2.71.
Conclusion
To sum up, Macrogenics Inc (MGNX) has seen a bad performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
